RE:RE:Market Exclusivity for 'novel' biological drug productsONCY's multiple clinical trials are demonstrating that ONCY's platform drug in pelareorep is able to turn cold tumors "hot" with the advantage of overcoming T-cell exhaustion, as discussed earlier.